Current Knowledge Regarding the Investigational 13-valent Pneumococcal Conjugate Vaccine
This article, published in Expert Reviews of Vaccines, explains the latest knowledge about the investigational 13-valent pneumococcal conjugate vaccine (PCV-13). It outlines the composition of the vaccine and the trials it has undergone to date for immunogenicity, noninferiority, and safety. It also discusses coadministration of the vaccine with other pediatric vaccines and details regarding the vaccine's serotype coverage. The authors confirm that clinical trials have shown PCV-13 to be safe and well tolerated with other pediatric vaccines in infants. They include a discussion of what the addition of new serotypes could mean for increasing protection against pneumococcal strains throughout the world. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Dinleyici EC, Yargic ZA
Visit web page (English)
(Located at www.expert-reviews.com)
Citation: Dinleyici EC, Yargic ZA. Current Knowledge Regarding the Investigational 13-valent Pneumococcal Conjugate Vaccine. Expert Review of Vaccines. 2009;8(8):977-986.